Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets, USP CII) 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Oxycodone HCl and acetaminophen is... Read More

Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus. The new facility, located at 144 Ludlow Avenue in Northvale, New Jersey, includes packaging, inventory and warehouse... Read More

Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended December 31, 2024, which is the third quarter of the Company's... Read More

Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025 Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2025 fiscal year will be released on... Read More

Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the... Read More

Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Hydrocodone and... Read More

Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse®... Read More

Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's... Read More

Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released... Read More

Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced the Israeli Ministry of Health approval for Elite's generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate,... Read More

Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets. Acetaminophen and codeine phosphate tablets are... Read More

Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic methotrexate sodium 2.5 mg tablets. Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute... Read More

Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended June 30, 2024, which is the first quarter of the Company's fiscal... Read More

Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024 Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2025 fiscal year will be released on Wednesday, August 14,... Read More

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Consolidated revenues for Fiscal 2024 were $56.6 million, an increase of $22.4 million or... Read More

Financials for Fiscal Year 2024 Ended March 31, 2024 will be released on July 1, 2024 Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2024 fiscal year-end financial results on Monday, July 1, 2024. Elite's management will host a live... Read More

NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as... Read More

Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the third quarter of fiscal year 2024 ended December 31, 2023 ("Third Quarter"). Consolidated... Read More

Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024 NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2024 fiscal year will be released on Wednesday, February 14, 2024.... Read More

NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product... Read More

NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced the first shipment of generic Adderall XR® to its distribution and marketing partner Prasco, LLC ("Prasco"). Adderall XR® is an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine... Read More

Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the second quarter of fiscal year 2024 ended September 30, 2023 ("Second Quarter"). Consolidated... Read More

Financials for Second Quarter Fiscal Year 2024 Ended September 30, 2023 will be released on November 14, 2023 NORTHVALE, NJ / ACCESSWIRE / November 10, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2024 fiscal year will be released on Tuesday, November 14, 2023.... Read More

NORTHVALE, NJ / ACCESSWIRE / September 25, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023... Read More

NORTHVALE, NJ / ACCESSWIRE / September 7, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the... Read More

NORTHVALE, NJ / ACCESSWIRE / August 28, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants . IQVIA reported... Read More

Conference Call Scheduled for Tuesday, August 15 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / August 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the first quarter of fiscal year 2024 ended June 30, 2023 ("First Quarter"). Consolidated revenues for the... Read More

Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023 NORTHVALE, NJ / ACCESSWIRE / August 9, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2024 fiscal year will be released on Monday, August 14, 2023. Elite's... Read More

Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 ("Fiscal 2023"). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared... Read More

Financials for Fiscal Year 2023 Ended March 31, 2023 will be released on June 29, 2023 NORTHVALE, NJ / ACCESSWIRE / June 22, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2023 year-end financial results on Thursday, June 29, 2023. Elite's management will host a live conference call... Read More

NORTHVALE, NJ / ACCESSWIRE / May 3, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in... Read More

NORTHVALE, NJ / ACCESSWIRE / April 20, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for... Read More

Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2023 ended December 31, 2022 ("Third Quarter"). Consolidated revenues for the three-month period ended December 31,... Read More

Financials for Third Quarter Fiscal Year 2023 Ended December 31, 2022 will be released on February 14, 2023 NORTHVALE, NJ / ACCESSWIRE / February 8, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2023 fiscal year will be released on Tuesday, February 14, 2023.... Read More

NORTHVALE, NJ / ACCESSWIRE / February 7, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of... Read More

NORTHVALE, NJ / ACCESSWIRE / December 22, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists. For the... Read More

Conference Call Scheduled for Tuesday, August 16 at 11:30 AM EDT Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2023 ended June 30, 2022 ("First Quarter"). Consolidated revenues for the three-month period ended June 30, 2022, were $7.7 million, an increase of $0.62 million or 9% as... Read More

Financials for First Quarter Fiscal Year 2023 Ended June 30, 2022 will be released on August 15, 2022 Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2023 fiscal year will be released on Monday, August 15, 2022. Elite's management will host a live conference call Tuesday,... Read More

Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2022 ("Fiscal 2022"). Consolidated revenues for Fiscal 2022 were $32.3 million, an increase of $6.9 million or 27% as compared to the comparable period of the prior fiscal... Read More

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet. Vigabatrin is an antiepileptic drug indicated for refractory complex... Read More

Financials for Fiscal Year 2022 Ended March 31, 2022 will be released on June 29, 2022 Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2022 year-end financial results on Wednesday, June 29, 2022. Elite's management will host a live conference call Thursday, June 30 th at 11:30 AM EDT to discuss... Read More

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer (CFO), effective May 16, 2022, succeeding Marc Bregman. Mr. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and... Read More

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that together with Elite's co-development partner, Praxgen Pharmaceuticals LLC, formerly SunGen Pharma LLC, ("Praxgen") received approval from the US Food and Drug Administration (FDA) for doxycycline hyclate 100 mg tablets. Doxycycline hyclate is an antibiotic that is... Read More